Register entry
- Registered sites
- 0
- Active NDC listings
- 38
- Live patents
- 259
- Exclusivities
- 5
- Countries
- 0
Catalogue
Drug listings by form and route
3838 active NDC listings: 38 human prescription drug. By marketing category: NDA 38.
| Dosage form | NDCs |
|---|---|
| tablet | 21 |
| kit | 13 |
| capsule | 2 |
| suspension | 1 |
| tablet, film coated | 1 |
| Route | NDCs |
|---|---|
| oral | 37 |
| Labeller name on the listing | NDCs |
|---|---|
| vanda pharmaceuticals inc. | 38 |
Exclusivity
Patents and exclusivities
259| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8586610 | FANAPTiloperidone | use | Nov 2027 |
| 10570453 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Mar 2028 |
| RE43728 | PONVORYponesimod | substance, product | Nov 2029 |
| 9157121 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Apr 2030 |
| 10563259 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Jul 2030 |
| 8652776 | FANAPTiloperidone | use | Aug 2030 |
| 12606869 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Sept 2030 |
| 8999638 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Oct 2030 |
| 9074255 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Dec 2030 |
| 9072742 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Jan 2031 |
| 9074256 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Feb 2031 |
| 9074254 | BYSANTI, FANAPTiloperidone; milsaperidone | use | Dec 2031 |
| 9062014 | PONVORYponesimod | substance, product | May 2032 |
| 10149829 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 10449176 | HETLIOZtasimelteon | use | Jan 2033 |
| 10610510 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 10945988 | HETLIOZtasimelteon | use | Jan 2033 |
| 10980770 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11285129 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11633377 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11826339 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11833130 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11850229 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 11918557 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 12201604 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 9060995 | HETLIOZtasimelteon | use | Jan 2033 |
| 9539234 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jan 2033 |
| 9549913 | HETLIOZtasimelteon | use | Jan 2033 |
| 9855241 | HETLIOZtasimelteon | use | Jan 2033 |
| RE46604 | HETLIOZtasimelteon | use | Jan 2033 |
| 11918556 | HETLIOZ, HETLIOZ LQtasimelteon | use | Apr 2033 |
| 9730910 | HETLIOZ, HETLIOZ LQtasimelteon | use | May 2034 |
| 10610511 | HETLIOZ, HETLIOZ LQtasimelteon | use | Oct 2034 |
| 11141400 | HETLIOZ, HETLIOZ LQtasimelteon | use | Oct 2034 |
| 11786502 | HETLIOZ, HETLIOZ LQtasimelteon | use | Oct 2034 |
| 10071977 | HETLIOZ, HETLIOZ LQtasimelteon | substance, product | Feb 2035 |
| 10829465 | HETLIOZ, HETLIOZ LQtasimelteon | substance, product | Feb 2035 |
| 11566011 | HETLIOZ, HETLIOZ LQtasimelteon | substance, product | Feb 2035 |
| 11760740 | HETLIOZ, HETLIOZ LQtasimelteon | substance, product | Feb 2035 |
| 12049457 | HETLIOZ, HETLIOZ LQtasimelteon | substance, product | Feb 2035 |
| 10376487 | HETLIOZ, HETLIOZ LQtasimelteon | use | Jul 2035 |
| 10179119 | HETLIOZ, HETLIOZ LQtasimelteon | use | Aug 2035 |
| 11266622 | HETLIOZ, HETLIOZ LQtasimelteon | use | Aug 2035 |
| 10220023 | PONVORYponesimod | use | Dec 2035 |
| 12336980 | PONVORYponesimod | use | Dec 2035 |
| 10772880 | NEREUStradipitant | use | Mar 2036 |
| 10821099 | NEREUStradipitant | use | Mar 2036 |
| 11324735 | NEREUStradipitant | use | Mar 2036 |
| 12318375 | NEREUStradipitant | use | Aug 2036 |
| 11202770 | HETLIOZ LQtasimelteon | product | Dec 2040 |
| 12447141 | HETLIOZ LQtasimelteon | use | Dec 2040 |
| 11759446 | HETLIOZ, HETLIOZ LQtasimelteon | use | Feb 2041 |
| 11951097 | PONVORYponesimod | use | Oct 2042 |
| 12478619 | BYSANTImilsaperidone | use | May 2044 |
| Product | Exclusivity | Until |
|---|---|---|
| BYSANTIMILSAPERIDONE | NCE New chemical entity | Feb 2031 |
| FANAPTILOPERIDONE | I-939 New indication | Apr 2027 |
| HETLIOZTASIMELTEON | ODE-330 Orphan drug | Dec 2027 |
| HETLIOZ LQTASIMELTEON | ODE-329 Orphan drug | Dec 2027 |
| NEREUSTRADIPITANT | NCE New chemical entity | Dec 2030 |
Catalogue
Marketed products
38| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-701NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-702NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-704NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-706NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-708NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-710NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-712NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-713NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-714NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-715NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-908NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-910NDA |
| BYSANTI | MILSAPERIDONE | tablet, oral | 43068-911NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-912NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-913NDA |
| BYSANTI | MILSAPERIDONE | kit, oral | 43068-914NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-101NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-102NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-104NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-106NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-108NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-110NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-112NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-113NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-114NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-115NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-901NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-902NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-903NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-904NDA |
| FANAPT | ILOPERIDONE | tablet, oral | 43068-905NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-906NDA |
| FANAPT | ILOPERIDONE | kit, oral | 43068-907NDA |
| Hetlioz | tasimelteon | capsule, oral | 43068-220NDA |
| Hetlioz LQ | tasimelteon | suspension, oral | 43068-304NDA |
| NEREUS | TRADIPITANT | capsule, oral | 43068-585NDA |
| PONVORY | Ponesimod | kit | 43068-610NDA |
| PONVORY | Ponesimod | tablet, film coated, oral | 43068-620NDA |
Compare
Other companies listing iloperidone
- Viyash Scientific Limited9 sites · 58 NDC
- PROCOS SpA1 site · 42 NDC
- MSN Organics Private Limited1 site · 30 NDC
Enquiry
Common questions
- Is Vanda Pharmaceuticals Inc. FDA approved?
- Vanda Pharmaceuticals Inc. holds no registered establishment of its own; 38 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Vanda Pharmaceuticals Inc. make?
- 38 products are listed under Vanda Pharmaceuticals Inc. in the openFDA NDC Directory, most often as tablet; kit; capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.